| Han Sibei,Guan Song,Li Na,et al.Impact of the estimated radiation dose to immune cells on the prognosis of stage Ⅲ non-small cell lung cancer in the era of immunotherapy[J].Chinese Journal of Radiological Medicine and Protection,2026,46(1):50-56 |
| Impact of the estimated radiation dose to immune cells on the prognosis of stage Ⅲ non-small cell lung cancer in the era of immunotherapy |
| Received:December 24, 2024 |
| DOI：10.3760/cma.j.cn112271-20241224-00492 |
| KeyWords:Immunotherapy Radiotherapy Chemotherapy Non-small cell lung cancer |
| FundProject:天津市医学重点学科(专科)建设项目(TJYXZDXK-009A) |
| Author Name | Affiliation | E-mail | | Han Sibei | Department of Radiotherapy, Cancer Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China
Department of Oncology, The 983th Hospital of the PLA Joint Logistics Support Force, Tianjin 300020, China | | | Guan Song | Department of Radiotherapy, Capital Medical University Beijing Chest Hospital, Beijing 300060, China | | | Li Na | Department of Radiotherapy, Tangshan People's Hospital, Tangshan 063001, China | | | Zhu Zixi | Department of Radiotherapy, Cancer Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China | zhaolujun@tjmuch.com | | Wang Wei | Department of Radiotherapy, Cancer Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China | | | Zhao Lujun | Department of Radiotherapy, Cancer Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China | wuyunyun@nirp.chinacdc.cn |
|
| Hits: 5426 |
| Download times: 603 |
| Abstract:: |
| Objective To explore the impact of the estimated dose of radiation to immune cells (EDRIC) on the prognosis of stage Ⅲ non-small cell lung cancer (NSCLC) patients who received immunotherapy and chemoradiotherapy in the era of immunotherapy. Methods A retrospective analysis was performed on the clinical data of 192 patients with stage Ⅲ NSCLC who underwent immunotherapy and chemoradiotherapy at the Cancer Hospital of Tianjin Medical University from January 2018 to June 2023. The radiation dose received by circulating blood immune cells was calculated using the EDRIC formula. The Kaplan-Meier method was used to analyze the overall survival (OS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS). The relationship between potential prognostic factors and survival indicators was analyzed using univariate and multivariate Cox proportional hazards regression models. Results The median OS, LPFS and DMFS of the whole cohert were 36.0 months, 22.0 months and 25.0 months, respectively, with a median EDRIC of 6.4 Gy. Patients with EDRIC <6.4 Gy had significantly longer median OS (χ2 = 7.92,P = 0.005) and median DMFS (χ2 = 4.56,P = 0.033) than those with EDRIC ≥ 6.4 Gy. Multivariate Cox regression analysis confirmed that EDRIC was significantly correlated with OS and DMFS. Stratified by clinical stage: in stage ⅢA patients, median OS (χ2 = 5.46,P = 0.020) and median DMFS (χ2 = 6.21,P = 0.013) were significantly longer in the EDRIC < 6.4 Gy group than in the EDRIC ≥ 6.4 Gy group; in stage ⅢB patients, there were no significant differences in median OS (P = 0.240), LPFS (P = 0.685), or DMFS (P = 0.639) between the two EDRIC subgroups; in stage ⅢCpatients, median LPFSwas significantly longer in the EDRIC ≥ 6.4Gy group (χ2 = 10.36, P = 0.001), while median OS (P = 0.383) and DMFS (P = 0.975) shoowed no significant differences. Conclusions EDRIC is an independent prognostic risk factor for stage Ⅲ NSCLC patients treated with immunotherapy and chemoradiotherapy. A higher EDRIC is associated with poorer prognosis, particularly in stage ⅢA patients with relatively smaller tumor burden. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
